IMMATICS BIOTECHNOLOGIES

immatics-biotechnologies-logo

immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficie... ncy, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche.

#SimilarOrganizations #People #Financial #Website #More

IMMATICS BIOTECHNOLOGIES

Social Links:

Industry:
Biotechnology Medical Therapeutics

Founded:
2000-01-01

Address:
Tübingen, Baden-Wurttemberg, Germany

Country:
Germany

Website Url:
http://www.immatics.com

Total Employee:
51+

Status:
Active

Contact:
(707) 153-970

Email Addresses:
info@immatics.com

Total Funding:
446.23 M USD

Technology used in webpage:
IPv6 Strato Strato DNS


Similar Organizations

advicenne-logo

Advicenne

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare kidney diseases.

aelis-farma-logo

Aelis Farma

Aelis Farma is a biotech company conducting research and development on innovative signaling specific drugs

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

amunix-logo

Amunix

Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics.

argen-x-logo

arGEN-X

arGEN-X offers a platform for antibody lead choice that supports the discovery of human antibody therapeutics.

aveo-oncology-logo

AVEO Oncology

AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.

barofold-logo

BaroFold

BaroFold is a biopharmaceutical company focused on the development of protein therapeutics for immunology indications.

cellcentric-logo

CellCentric

CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.

cellmover-logo

Cellmover

Cellmover specializes in the development of therapeutics for cancer immunotherapy.

ciloa-logo

Ciloa

Ciloa is a uniquely positioned to support your projects aiming to create new therapeutic.

codiak-biosciences-logo

Codiak Biosciences

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

collegium-pharmaceutical-logo

Collegium Pharmaceutical

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.

curevac-logo

CureVac

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.

diamedica-logo

DiaMedica

DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke.

enara-bio-logo

Enara Bio

Ervaxx is illuminating the immune interface to develop new cancer therapies.

gadeta-logo

Gadeta

Gadeta is a research and development company that develops immunotherapies for cancer.

igm-biosciences-logo

IGM Biosciences

IGM Biosciences is a biotechnology company pioneering the development of engineered IgM antibodies.

precigen-logo

Precigen

Precigen is a life sciences company researching and developing bio-therapeutic control systems to minimize toxicity.

liquidia-technologies-logo

Liquidia Technologies

Liquidia Technologies is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics.

mabvax-therapeutics-logo

MabVax Therapeutics

MabVax is a biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.

mireven-logo

MiReven

MiReven is a biopharmaceutical company focused on developing miR-7 as a cancer therapy.

neximmune-logo

NexImmune

NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.

nflection-therapeutics-logo

NFlection Therapeutics

NFlection focuses on the development of novel therapies to address the needs of patients.

nucana-biomed-logo

NuCana BioMed

NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.

occurx-logo

OccuRx

OccuRx is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies.

oncology-pharma-logo

Oncology Pharma

Oncology Pharma is engages in research and development of therapeutics for oncology.

piqur-therapeutics-logo

PIQUR Therapeutics

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.

proteostasis-therapeutics-logo

Proteostasis Therapeutics

Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.

rhovac-aps-logo

Rhovac ApS

RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells.

sensorion-logo

Sensorion

Sensorion is a France-based biopharmaceutical company developing targeted therapeutic solutions for the treatment of vestibular deficits.

spark-therapeutics-logo

Spark Therapeutics

Spark Therapeutics is focused on the development of gene therapy.

springworks-therapeutics-logo

SpringWorks Therapeutics

SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.

telomium-logo

Telomium

Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy.

theranexus-logo

Theranexus

Theranexus is a clinical-stage pharmaceutical company that aims to develop technology to address severe medical needs in brain disorders.

umandiagnostics-logo

UmanDiagnostics

UmanDiagnostics supplies neurofilament light (Nf-L) antibodies and ELISA kits to advance the development of therapeutics and diagnostics.


Current Advisors List

friedrich-bohlen_image

Friedrich Bohlen Member of the Board of Directors @ immatics biotechnologies
Board_member

peter-chambre_image

Peter Chambre Chairman of the Board of Directors @ immatics biotechnologies
Board_member
2012-11-01

christof-hettich_image

Christof Hettich Member of the Board of Directors @ immatics biotechnologies
Board_member

craig-slingluff_image

Craig Slingluff Member of the Scientific Advisory Board @ immatics biotechnologies
Advisor

harald-stock_image

Harald Stock Member of the Board of Directors @ immatics biotechnologies
Board_member

christoph-huber_image

Christoph Huber Member of the Scientific Advisory Board @ immatics biotechnologies
Advisor

pedro-romero_image

Pedro Romero Member of the Scientific Advisory Board @ immatics biotechnologies
Advisor

cornelius-melief_image

Cornelius Melief Member of the Scientific Advisory Board @ immatics biotechnologies
Advisor

Current Employees Featured

carolin-mauch_image

Carolin Mauch
Carolin Mauch Associate Director Financial Planning & Analysis @ immatics biotechnologies
Associate Director Financial Planning & Analysis

martin-hofmann_image

Martin Hofmann
Martin Hofmann Associate Director Immunology @ immatics biotechnologies
Associate Director Immunology
2019-07-01

norbert-hilf_image

Norbert Hilf
Norbert Hilf VP Translational Development @ immatics biotechnologies
VP Translational Development
2018-01-01

martina-ott_image

Martina Ott
Martina Ott Associate Director Target Validation @ immatics biotechnologies
Associate Director Target Validation

arun-satelli_image

Arun Satelli
Arun Satelli Associate Director @ immatics biotechnologies
Associate Director
2017-12-01

steffen-walter_image

Steffen Walter
Steffen Walter Chief Technology Officer @ immatics biotechnologies
Chief Technology Officer
2020-06-01

arnd-christ_image

Arnd Christ
Arnd Christ Chief Financial Officer @ immatics biotechnologies
Chief Financial Officer
2020-10-01

toni-weinschenk_image

Toni Weinschenk
Toni Weinschenk CTO @ immatics biotechnologies
CTO
2017-09-01

sonja-dorner_image

Sonja Dorner
Sonja Dorner Associate Director @ immatics biotechnologies
Associate Director
2019-01-01

frank-schwöbel_image

Frank Schwöbel
Frank Schwöbel Associate Director Preclinical Pharmacology & Pharmacokinetics @ immatics biotechnologies
Associate Director Preclinical Pharmacology & Pharmacokinetics
2017-10-01

Founder


hans-rammensee_image

Hans Rammensee

harpreet-singh_image

Harpreet Singh

steffen-walter_image

Steffen Walter

Stock Details


Company's stock symbol is NASDAQ:IMTX

Investors List

at-impf_image

AT Impf

AT Impf investment in Post-IPO Equity - immatics biotechnologies

dievini-hopp-biotech-holding_image

dievini Hopp Biotech Holding

dievini Hopp Biotech Holding investment in Post-IPO Equity - immatics biotechnologies

redmile-group_image

Redmile Group

Redmile Group investment in Post-IPO Equity - immatics biotechnologies

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Post-IPO Equity - immatics biotechnologies

wellington-partners_image

Wellington Partners

Wellington Partners investment in Post-IPO Equity - immatics biotechnologies

sphera-funds-management_image

Sphera Funds Management

Sphera Funds Management investment in Post-IPO Equity - immatics biotechnologies

rtw-investments-llc_image

RTW Investments LLC

RTW Investments LLC investment in Post-IPO Equity - immatics biotechnologies

celgene_image

Celgene

Celgene investment in Venture Round - immatics biotechnologies

wellington-partners_image

Wellington Partners

Wellington Partners investment in Series E - immatics biotechnologies

dievini-hopp-biotech-holding_image

dievini Hopp Biotech Holding

dievini Hopp Biotech Holding investment in Series E - immatics biotechnologies

Official Site Inspections

http://www.immatics.com Semrush global rank: 2.22 M Semrush visits lastest month: 8.71 K

  • Host name: ds187313.goserver.host
  • IP address: 185.30.33.118
  • Location: Germany
  • Latitude: 51.2993
  • Longitude: 9.491
  • Timezone: Europe/Berlin

Loading ...

More informations about "immatics biotechnologies"

immatics biotechnologies - Crunchbase Company …

Organization. immatics biotechnologies . Connect to CRM . Save . Summary. …See details»

Immatics Company Profile - Office Locations, Competitors ... - Craft

Oct 29, 2024 Immatics has 5 employees across 4 locations and €155.84 m in annual revenue in FY 2024. See insights on Immatics including office locations, competitors, revenue, financials, …See details»

Immatics - LinkedIn

Immatics | 25,896 followers on LinkedIn. Delivering the Power of T Cells to Patients with Cancer | Immatics combines the discovery of true targets for …See details»

Immatics - pharmaceutical Technology

Immatics’ approach towards the goal of opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets (using the XPRESIDENT ® platform). In …See details»

immatics - VentureRadar

" immatics biotechnologies GmbH, founded 2000 at Tubingen's Department of Immunology, capitalizes on groundbreaking discoveries investigating the role of tumor-associated peptides …See details»

Immatics - Overview, News & Similar companies | ZoomInfo.com

Nov 14, 2023 Immatics Announces Third Quarter 2023 Financial Results and Business Update Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: …See details»

Locations - Immatics

Immatics operates as a transatlantic organization with the team spanning from Tübingen and Munich, Germany to Houston, Texas. The long-term integration of the European and US sites …See details»

Locations – Immatics

Immatics operates as a transatlantic organization with the team spanning from Tübingen and Munich, Germany to Houston, Texas. The long-term integration of the European and US sites …See details»

Immatics: Revenue, Worth, Valuation & Competitors 2025

Immatics has an estimated revenue of $111M, and 552 employees. Alternatives of Immatics are Imaging Endpoints, Southern Scripts and Alfasigma USA. ... Organization Immatics …See details»

Investors & Media | Immatics N.V.

Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 Tuebingen Germany. Phone: +49 7071 5397-0 Fax: +49 7071 5397-900 E-Mail: info@immatics.com. Immatics US, Inc. 13203 …See details»

Immatics NV - Drug pipelines, Patents, Clinical trials - Synapse

BMS and Immatics started working together in 2019, when the pharma company spent $75 million upfront on options for three of the biotech’s T cell receptor therapy targets. Two years later, …See details»

About - Immatics

In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies. Immatics N.V. …See details»

About – Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response …See details»

Jobs - Immatics

Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 – 19 72076 Tuebingen Germany. Phone: +49 7071 5397-0 Fax: +49 7071 5397-900 E-Mail: info@immatics.com. …See details»

Technologies – Immatics

Immatics’ approach to opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets using the XPRESIDENT ® platform. XPRESIDENT ® …See details»

Careers - Immatics

Fundamentally, Immatics is its employees: Like every organization, our corporate culture is wholly defined by the team and the systems set in place to facilitate an innovative, collaborative, …See details»

Pipeline - Immatics

In these partnerships, Immatics seeks to evaluate and develop programs based on novel Immatics-derived targets in a variety of immunotherapeutic approaches. From its research and …See details»

Immatics – Delivering the power of T cells to cancer patients

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell …See details»

immatics n.v. announces upcoming annual general meeting

1 day ago The company, previously known as Immatics B.V., changed its name in April 2020. The filing, submitted under Form 6-K, is part of the company’s compliance with the Securities …See details»

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 …

4 days ago Stafford, Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the …See details»

linkstock.net © 2022. All rights reserved